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Abstract
Accumulating evidence suggests that the response of bacteria to antibiotics is significantly affected by the presence of other
interacting microbes. These interactions are not typically accounted for when determining pathogen sensitivity to antibiotics.
In this perspective, we argue that resistance and evolutionary responses to antibiotic treatments should not be considered
only a trait of an individual bacteria species but also an emergent property of the microbial community in which pathogens
are embedded. We outline how interspecies interactions can affect the responses of individual species and communities to
antibiotic treatment, and how these responses could affect the strength of selection, potentially changing the trajectory of
resistance evolution. Finally, we identify key areas of future research which will allow for a more complete understanding of
antibiotic resistance in bacterial communities. We emphasise that acknowledging the ecological context, i.e. the interactions
that occur between pathogens and within communities, could help the development of more efficient and effective antibiotic
treatments.
Introduction
The global use and misuse of antibiotics has led to the
evolution and spread of bacterial resistance to all routinely
used antibiotics. In order to effectively tackle the spread of
antimicrobial resistance (AMR) through antimicrobial
stewardship or development of novel antimicrobial com-
pounds, understanding how bacteria adapt and evolve to
survive antibiotic treatments is crucial. Here we argue that to
fully understand the evolution of AMR we must study the
emergence of resistance within the context of microbial
communities. While the composition, structure and interac-
tions within microbial populations are known to affect the
horizontal gene transfer (HGT) of antibiotic resistance [1–3],
it is becoming evident that intra- and interspecies interac-
tions also influence how species respond and evolve under
antibiotic exposure within microbial communities. As a
result, clinical susceptibility to antibiotics might not translate
well to the successful treatment of polymicrobial infections
where pathogens are typically embedded in complex mul-
tispecies microbial communities. Interspecies interactions
are not typically accounted for when assessing antibiotic
sensitivity and resistance evolution in the context of anti-
biotic treatments. In this perspective, we focus on the role
of interspecies bacterial interactions on the selection of pre-
existing resistance, and on how interactions within bacterial
communities could change the evolutionary trajectory of
de novo resistance, i.e., the evolutionary dynamics and
outcomes of antibiotic exposure, particularly within a clin-
ical context.
The ability of a bacterial strain to survive antibiotic
exposure is commonly assessed in monoculture measure-
ments of growth, through broth microdilution or agar
dilution assays, to quantify a minimum inhibitory con-
centration (MIC) [4]. These in vitro methods test the sus-
ceptibility of individual bacterial strains determining MIC
breakpoints and providing informed choices of anti-
microbial interventions. However, our understanding and
interpretation of MIC measurements has improved in recent
years. Higher initial population densities can result in lower
susceptibility to some antibiotics, a phenomenon called the
inoculum effect [5, 6]. In addition, biofilm growth can
dramatically increase the effective MIC of a population and
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alter the rates of resistance evolution when compared to
planktonic cells [7, 8]. Finally, it is increasingly evident that
sub-MIC antibiotic concentrations can positively select for
resistance mutations, increase HGT of antimicrobial resis-
tance genes (ARGs), and elevate mutation rates; all of
which will increase the likelihood of resistance evolution
[9–12]. As such the minimal selective concentration (MSC)
and predicted no effect concentration have become impor-
tant metrics for understanding and controlling the evolution
and spread of resistance [13].
The effect of ecological context, i.e., the type and
dynamics of microbial interactions that occur between
pathogens and the surrounding community, is often over-
looked when considering antibiotic efficacy and the evolu-
tion of resistance. We currently predominantly consider
antibiotic sensitivity as an independent trait of an individual
strain. However, it is clear that inter- and intra-species
interactions within both clinical and environmental com-
munities, as well as the physical properties of the associated
microbial community, can alter the physiological state and
antibiotic susceptibility of bacteria [14]. Interspecies inter-
actions are especially common in polymicrobial infections
where multiple species contribute to disease [15]. These
interactions not only affect the severity of infections but
could also alter the exposure and physiological responses to
antibiotics. We thus argue that bacterial ability to withstand
antibiotic treatments, and the consequent evolution of
resistance to those treatments, should be viewed as an
emergent property of a microbial community rather than
simply a trait of a particular species.
To discuss the effects of antimicrobial exposure on
microbial communities we must first distinguish the dif-
ferent ways in which bacteria survive in the presence of
antibiotics. Resistance is often defined as the inheritable
ability of a cell to grow at high concentrations of an anti-
biotic, irrespective of the duration of exposure [16]. Its
mechanisms are many and varied [17]. Resistance can be
intrinsic, whereby the physiological properties of all mem-
bers of a species allow it to resist the action of certain
antibiotics; or acquired, either through de novo mutation or
via the acquisition of ARGs via HGT. However, bacterial
populations can also survive antibiotic treatment without
encoding specific resistance mechanisms. Tolerance
describes the ability of a bacterial population to survive
transient exposure to a high concentration of an antibiotic
without a change in their MIC [16]. This is often mediated
by a change in the physiological state of the cells within a
population due to their environmental context, such as
slowing down essential cellular processes following a lack
of resources [18], interactions with a host’s immune system
[19] or interactions with other bacterial species [20],
resulting in a reduced death rate in the presence of anti-
biotic. Alternatively, tolerance can be a heritable and
evolvable trait, as has been demonstrated in the evolution of
tolerance through the optimisation of lag-times to match the
intervals of antibiotic exposure [21]. Whereas resistance and
tolerance are considered properties of a population, persis-
tence describes the ability of a small sub-population of a
clonal bacterial population to enter a state of dormancy,
allowing it to survive high concentrations of antibiotic while
the rest of the population is rapidly killed [22, 23]. Both
tolerance and persistence allows surviving bacteria to
resume normal growth after the depletion of the antibiotic.
Interspecies interactions can alter responses
to antibiotics
Interspecies interactions can have a profound effect upon
the outcome of antibiotic treatment. We define three main
ways in which bacterial communities, or subpopulations of
communities, can survive exposure to antimicrobials due to
interspecies interactions: (1) Collective resistance, interac-
tions within a community that elevate the ability of its
members to resist the action of an antibiotic and continue to
grow in the presence of antibiotics thus increasing the MIC
of the community. (2) Collective tolerance, interactions
within a community that alter cell state, such as slowing
down metabolism, and thus slow down the rate of cell death
during transient exposure to antibiotics without an increase
in MIC. (3) Exposure protection, interactions within a
community that protect its sensitive members during anti-
biotic treatment by reducing the effective concentration of
antibiotic [24, 25]. These definitions are not mutually
exclusive; interactions could have multiple different effects,
and multiple different mechanisms may act simultaneously
within a community.
Many of the known mechanisms that provide collective
resistance, tolerance or exposure protection are density-
dependent, providing protection to large, dense populations
[25] through the inactivation of antibiotics, biofilm forma-
tion and quorum sensing-activated responses [26–28].
While such interactions are often considered to take place
among cells of the same (or closely related) genotypes, the
same mechanisms can also occur between different geno-
types or species in diverse multi-species communities. For
example, an analysis of the multi-species networks of
urinary tract infections showed that clinical isolates from the
same patient often protect each other from antibiotics, with
the protective effects correlating with interspecies interac-
tions that foster growth benefits [29]. However, the majority
of interactions within multispecies communities are argued
to be competitive, with most pairwise interactions resulting
in a net reduction in community productivity [29, 30].
Disruption of the complex network of interactions within
communities, whether cooperative or competitive, through
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exposure to antimicrobials will thereby alter community
structure and change the growth and survival of its con-
stituent members.
Resistance mechanisms that inactivate antibiotics are
widespread, providing both acquired and intrinsic resistance
to some of the most widely used antibiotics including
aminoglycosides, chloramphenicol and β-lactams. Such
resistance mechanisms can be considered as cooperative
traits; the benefit of antibiotic inactiaving enzyme produc-
tion is not confined to the producer, rather it is shared
across the community [31, 32]. Cooperative enzymatic
inactivation provides exposure protection through reducing
the environmental concentration of an antibiotic (Fig. 1a),
which can be exploited by sensitive members of the same,
and different, species within a community [26, 33–35]. For
example, the enzymatic inactivation of β-lactam antibiotics
via β-lactamase producing Escherichia coli can protect
Salmonella enterica serovar Typhimurium from con-
centrations of antibiotic that would usually kill them [33].
The presence of β-lactamases has been reported in a wide
range of clinical samples taken from polymicrobial infec-
tions (reviewed in [36]) suggesting that they likely con-
tribute to the resilience of infections to β-lactam antibiotics.
The benefit of antibiotic inactivation is not limited to peri-
plasmic or secreted enzymes; the intracellular inactivation
of chloramphenicol by Staphylococcus aureus or Strepto-
coccus pneumoniae, via a plasmid borne acetyltransferase,
allows the survival of sensitive S. pneumoniae through the
detoxification of the local environment in liquid culture, on
semi-solid surfaces and in in vivo mouse models [26].
Computational modelling suggests that the benefits of such
cooperative antibiotic inactivation is greatest when com-
munity interactions are mutualistic, as mutualism drives the
spatial mixing of the communities and hence the sharing of
the benefit of antibiotic inactivation [37]. As a result, anti-
biotic inactivation could provide protection to a microbial
community allowing sensitive members of the community
to survive otherwise lethal antibiotic treatments.
Collective resistance, collective tolerance and exposure
protection to antibiotics can also be provided through bio-
film formation (Fig. 1b). Bacterial biofilms comprise of
cells growing as aggregates surrounded by a self-secreted
polymer matrix of exopolysaccharides, DNA and proteins.
Biofilms provide exposure protection to their members
through limiting the diffusion of antibiotics into the popu-
lation [38] and increasing the protection provided by
Fig. 1 Community interactions, as well as resistance genotype,
affect the response to antibiotic exposure. In all panels, cell growth
state is represented by either hatched (unable to grow) or solid fill (able
to grow). a Resistant bacteria that inactivate antibiotics reduce the
local antibiotic concentration, providing exposure protection to sur-
rounding sensitive species. This benefit is dependent upon the density
and spatial structure of the population, as well as the diffusion rate and
rate of inactivation of the antibiotic. b Some species are unable to form
biofilms in isolation but are able to gain improved antibiotic tolerance
by participating in established biofilms of other species. c The receipt
of secreted signalling molecules, such as indole and DSF, can trigger
antibiotic resistance states in otherwise susceptible community mem-
bers through increasing the expression of resistance genes. d Reliance
upon cross-feeding networks can be detrimental for a resistant species
if its growth depends on cross-feeding on secretions of susceptible
community members. In this scenario, tolerance to antibiotics is
lowered to the level of the most susceptible community member as
cross-feeding interactions are lost due to antibiotic killing (dashed
white arrows) thus the resistant species is unable to grow due to the
loss of essential recourses.
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antibiotic inactivation [34]. In addition, biofilms can induce
tolerant cell states due to nutrient and oxygen gradients that
lead to a reduction in metabolic activity in the centre of the
biofilm [27], increasing the proportion of persister cells
within the population [23]. Biofilms can also increase levels
of resistance by altering the expression of pre-existing
ARGs [39]. Compared to single-species biofilms, inter-
species interactions within multi-species biofilms can lead
to further increases in survival during antibiotic treatment
through altering spatial structure of the biofilm, increasing
the expression of resistance mechanisms, and allowing for
individually expressed antimicrobial defences to protect the
whole community [40–42]. However, competition between
genotypes via the secretion of toxins [43–45] and the
seizing of space via the use of adhesins [46, 47] and matrix
production [48] may limit social mixing of different geno-
types within a biofilm and eradicate competing species [49].
Thus, competition may help to privatise public goods within
multi-species biofilms, limit between-genotype cooperation
and break down interactions that increase the ability of the
community to survive antibiotic treatment.
Much work on biofilms has focused on the interspecies
interactions within the lungs of Cystic Fibrosis (CF) patients,
where multi-species biofilm formation is common. Within
mixed biofilms Pseudomonas aeruginosa can cause a meta-
bolic shift in S. aureus, reducing its growth and providing S.
aureus with protection to vancomycin [50]. Reciprocally, S.
aureus can enhance tobramycin tolerance of P. aeruginosa by
increasing aggregation and altering biofilm architecture in CF
model systems [51]. However, the activity of antibiotics
against multi-species biofilms appears to depend on both
community composition and the antibiotic treatment, with
some combinations of bacterial species decreasing rates of
killing by antibiotics, while others had no effect [52]. Whether
interactions within biofilms facilitate or limit antibiotic resis-
tance or tolerance [53] might depend on the mode of the
interaction, i.e., direct cell contact versus diffusible molecules,
as the physical properties of the community alter the prob-
ability of cell-cell contact and diffusion rates.
Bacteria secrete a vast variety of compounds ranging
from signalling molecules involved in quorum sensing to
exotoxins involved in virulence and competition. Secreted
products within communities have been shown to directly
alter gene expression, metabolic processes and the growth
dynamics of co-residing bacterial species, altering their
ability to survive antibiotic exposure (Fig. 1c). For example,
interspecies signalling via the secretion of indole by E. coli
activates the expression of an indole-dependent multi-drug
efflux pump in Pseudomonas putida, which cannot produce
the indole itself, leading to elevated levels of resistance in
P. putida [54]. Likewise, the secretion of diffusible signal
factor by Stenotrophomonas maltophilia, a Gram-negative
bacterium that often co-occurs with P. aeruginosa during
polymicrobial pulmonary infection, alters P. aeruginosa
biofilm structure and stimulates the synthesis of proteins
that provide resistance to cationic antimicrobial peptides
such as polymyxin [55]. In addition to cellular cross talk,
exotoxins — presumably produced to inhibit the growth of
competitors — can promote the transition of competing
bacterial species into an antibiotic tolerant physiological
state. For example, P. aeruginosa induces highly tolerant
small colony variants of S. aureus through the secretion of
4-hydroxy-2-heptylquinoline-N-oxide, which inhibits the
electron transport chain, dramatically slowing down the
growth rate of S. aureus [20, 56]. Given the vast diversity of
bacterial secreted products, and the complexity of multi-
species communities, it is likely that we have barely scrat-
ched the surface of understanding how these secretions alter
antibiotic resistance and tolerance.
Competitive interactions, via interference or exploitation,
are prevalent within mixed bacterial communities due to
overlaps in metabolic requirements and limitation of space
[29, 30, 57]. Disruption or alteration in the intensity of
interspecies competition, or cooperation, through exposure
to antibiotics can alter community structure by making
otherwise inaccessible resources available for exploitation
by other members of the community. These changes in
community structure may alter the ability of component
members to survive antibiotic exposure. Antibiotic treat-
ment of brewery multi-species biofilms, which were domi-
nated by competitive interactions, resulted in reduced levels
of competition due to the inhibition of highly competitive
species within the population. This led to increased growth
of species that were otherwise suppressed within the
population [58] and in turn elevated the antibiotic tolerance
of these species, likely due to the density-dependent nature
of collective tolerance mechanisms. Similar results were
observed within experimental bacterial communities [59],
where antibiotic treatment benefited members of the com-
munity that had marginally elevated levels of tolerance. In
contrast, the mutualistic interaction of cross-feeding can
lead to inter-dependence between multiple species within a
community; thus lowering the antibiotic sensitivity of all
members of the cross-feeding network to that of the weakest
member of the consortium (Fig. 1d) [37, 60]. Taken toge-
ther, these findings suggest that how individuals and com-
munities respond to antibiotic exposure depends on a
complex network of interactions including social exploita-
tion, cooperation, competition and communication.
Ecological context can influence the
selection for antimicrobial resistance
How does a multi-species community alter the selection for
AMR within its members? The answer to this question
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depends upon the members of the community in question
and the specific interactions that occur between them.
Multiple interactions — including competition, exploita-
tion, commensalism and mutualism — take place in com-
munities and each of them has the potential to alter the
strength of selection acting upon resistance mechanisms of
its members. Consequently, AMR evolution within com-
munities may occur at different rates, result in different
magnitudes of resistance, or be associated with different
levels of cost compared to single species populations.
The presence of interacting species could further affect
the evolutionary trajectory of de novo resistance by chan-
ging which mutations and molecular mechanisms are
selected for.
Previous studies of the evolutionary dynamics of ARGs
have mostly focused on resistant and sensitive strains within
single-species populations [9, 32, 61]. These studies indi-
cate that the concentration of antibiotic required to posi-
tively select for resistant bacteria, MSC, is far below the
MIC of their sensitive counterparts [9, 61]. Low antibiotic
concentrations at the MSC may be non-lethal to the sensi-
tive strains, but they reduce the growth rate of sensitive cells
sufficiently to outweigh the inherent costs associated with
harbouring resistance [62–64]. Low levels of antibiotics
could thus already select for an increase in the abundance of
antibiotic resistant cells within a population (Fig. 2a/b).
There are few experimental studies comparing how anti-
biotic resistant and sensitive strains respond to antibiotic
selection in the absence and presence of other competing
bacteria. Klümper et al. [14] recently demonstrated that
complex multi-species anaerobic communities derived from
pig faeces can increase the concentration of antibiotics
required to select for resistant E. coli strains embedded
within the community. Mechanistically, it was shown that
this increase in MSC was caused either by protection of the
sensitive E. coli strain by the community (Fig. 2d) (as
previously shown with cooperative antibiotic inactivation in
single species populations [31, 32]) or through competition
elevating the magnitude of costs associated with the resis-
tance (Fig. 2c) with no resulting change in the MIC of the
sensitive strain [14]. More generally, these results are in line
with previous studies showing that competition can con-
strain bacterial adaptation [65] supporting the idea that
antagonistic bacteria-bacteria interactions are likely to limit
the evolution of antibiotic resistance in communities.
Interactions within a community that increase the prob-
ability of the survival of its sensitive members during
antibiotic exposure will also alter the selection dynamics of
ARGs within the community [31, 32]. When a resistant
strain provides protection to an otherwise sensitive strain
within a community, the MSC of resistance would be
expected to increase (Fig. 2d). This is because sensitive
strains would be able to outcompete resistant strains at
relatively higher concentrations of antibiotic [66]. However,
the selection dynamics of resistance would typically depend
upon the nature of protection provided by the community.
When protection is provided by a single resistant species,
for example through exposure protection via antibiotic
inactivation, selection for this resistant genotype would be
expected to follow negative frequency dependence. When
the resistant strain is rare exposure protection will be pre-
ferentially directed towards the resistant genotype. As the
resistant strain becomes more common, exposure protection
will be shared with a larger proportion of sensitive members
of the community and thus the relative fitness of the resis-
tant genotype will decrease. In addition, if protection is
provided by a single keystone species, protection might be
more vulnerable to stochastic events and density fluctua-
tions of the protective species. In contrast, if protection is
provided by multiple species present in the community, or
by the physical properties of the community (e.g., biofilm
matrix), collective resistance or tolerance would likely be
more stable due to relatively higher functional redundancy
of “protection” within the community. Ecological stability
of collective resistance and collective tolerance could thus
alter the length of antibiotic exposure, and therefore alter the
timescales in which selection for resistance can act [67, 68].
Inactivation of antibiotics may result in transient and short-
lived antibiotic exposure leading to changes at ecological
rather than evolutionary timescales, that is, changes in the
composition and frequencies of different species within the
community similar to the effect of ecological disturbances.
In contrast, interspecies interactions that increase antibiotic
tolerance may prolong antibiotic exposure at sub-inhibitory
concentrations, allowing the accumulation of de novo
mutations upon which selection can act [69] (in contrast to
>MIC selection which typically acts upon the standing
genetic variation within the population [Fig. 2e] [11]). Thus,
communities could alter the trajectory of resistance evolu-
tion, allowing the stepwise generation of low effect, low
cost resistance mutations that together provide high levels
of resistance (Fig. 2f). Similar results have been observed
during sub-MIC selection for resistance in S. enterica,
which resulted in changes in multiple different resistance
mechanisms at the molecular level, including alteration of
the ribosomal RNA target, reduction in antibiotic uptake
and induction of antibiotic-modifying enzymes [11].
Interspecies competition inherent to complex microbial
communities can also elevate the magnitude of cost of
resistance [14, 70], which may favour the selection for
low cost antibiotic resistance mutations, or alternatively,
increase the likelihood of compensatory mutations that
overcome the associated costs of resistance. Similar trade-
offs between cost and resistance have been observed when
comparing the evolution of resistance between planktonic
and biofilm lifestyles [71], with members of biofilms
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acquiring low cost mutations that provided overall lower
levels of resistance compared to resistance mutations
acquired during planktonic growth. Moreover, it has
recently been shown that bacterial resistance evolution to
phage can be changed in the presence of competitors from
more costly surface receptor-mediated resistance to less
costly CRISPR-based resistance [70]. While antibiotic
and phage resistances are not directly comparable, both
are mediated by multiple different mechanisms with
varying magnitudes of cost, and their evolutionary tra-
jectories could thus be similarly shaped by the presence of
competitors. More experimental studies are needed to
better understand the multiple ways interacting species
might affect antibiotic resistance evolution in microbial
communities.
Significance of interspecies interactions for
the success of antibiotic treatments
Even though interspecies interactions during polymicrobial
infections — as well as between focal pathogens and resi-
dent microbiota of the body, such as those found in the oral
cavity or gastrointestinal tract [72, 73] — are known to alter
the outcome of antibiotic treatments [74, 75], these inter-
actions are often overlooked. For example, relying on
Fig. 2 Fitness and selection consequences of differential effects of
antibiotic concentration on growth rate. a Theoretical max growth
rates in pure culture of ‘isogenic’ strains differing only in resistance or
sensitivity to antibiotic. Shaded area represents the range of antibiotic
concentrations in subsequent panels (b–d) exploring competition
outcomes and minimal selective concentration (MSC) based on these
relative growth rates. b The MSC is defined as the antibiotic con-
centration at which growth rate of the resistant strain exceeds that of
the sensitive strain (relative fitness >1). c, d In a community, the MSC
can be increased by two basic mechanisms. One is increased costs of
resistance, which may arise by increased competition for nutrients (c)
and the other is reduced antibiotic effect upon sensitive strains, which
may arise by community protection (d). e, f The emergence of de novo
resistance mutations can be altered by community protection. e In the
absence of a protective community antibiotic exposure above the MIC
acts upon standing genetic variation, often selecting for a single high
resistance, high cost mutation. e Communities that provide exposure
protection may reduce the realised antibiotic exposure to sub-MIC
levels, allowing for the sequential accumulation of low cost, low
resistance mutations that together provide high levels of resistance for
example via epistasis. Letters inside panels (S, R, A, AB, etc.)
represent the accumulation of different mutations during selective
sweeps.
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testing the antibiotic susceptibility of pathogens in mono-
cultures could confound our ability to select the most
appropriate antibiotics for clinical interventions because
these tests might not reliably reflect community-scale
responses. Indeed, in vitro antibiotic susceptibility does
not always translate to successful treatment of poly-
microbial infections, where disease is caused by multiple
interacting pathogens [76]. In fact, the response of indivi-
dual species to antibiotic treatment within a community can
be opposite to that in isolation, with sensitive species being
able to grow and tolerant species being inhibited in the
presence of antibiotic [77]. Given that many chronic
infections that require long term, repeat antibiotic treat-
ments — such as infections of the CF lung, urinary tract
and diabetic wounds — are caused by polymicrobial
communities, it is important to start considering how the
composition of bacterial communities modulates not only
disease severity but also the success of antibiotic treat-
ment outcomes [15, 78].
Culture-independent methods, such as 16S rRNA
sequencing and shotgun metagenomics, are providing an
increasingly detailed understanding of the composition of
microbiota during infections. These methods have allowed
for the tracking of community structure and species richness
within individual CF patients through time, across infection
types and during antibiotic treatment [79, 80], provided
detailed understanding of the response of host microbiota
during Clostridium difficile infection [81] and directly
identified resistance genes during polymicrobial urinary
tract [82] and bone and joint infections [83]. As our ability
to identify and track resistance determinants within micro-
bial communities improves, the prospect of using clinical
metagenomics to design personalised drug regimens
becomes more appealing [84]. Despite these advances, we
still face a major challenge in identifying which species are
interacting within microbial communities and how these
may alter both disease progression and the outcomes of
antimicrobial treatment. In most cases the specific interac-
tions during polymicrobial infection, or between focal
pathogens and the resident commensal communities, remain
unknown. To incorporate multi-species interactions into
future treatment design requires identification of not only
the species present, but also the interactions between them.
How can improved knowledge on microbial ecology be
translated into more effective treatment of polymicrobial
infections? A detailed and personalised understanding of the
microbial taxa present during polymicrobial infections,
along with the interactions between them, may facilitate
new approaches to antibiotic resistance [74]. Resistance
mechanisms that inactivate antibiotics have been the target
of inhibitory compounds, such as the co-treatment of β-
lactams with β-lactamase inhibitors [85] and such treat-
ments are commonly used in an attempt to overcome the
evolution of resistance within focal pathogen strains. In
addition, these interventions may be effective against
cooperative antibiotic inactivation mechanisms of other
members of multi-species communities that are protecting
focal pathogens from treatment. However, it is not clear
how communities affect the evolution of resistance towards
enzyme inhibitors [86]. Other cooperative virulence traits
such as EPS production are also vulnerable to perturbation;
inhibition of EPS production in S. enterica combined with
antibiotic treatment proved to be an evolutionarily robust
strategy to decrease collective tolerance and reduce the
probability of resistance evolution in vitro [87]. The
potency of such interventions targeting cooperative traits
within polymicrobial biofilms is yet to be investigated.
More combinatorial approaches targeting the disruption of
interactions that elevate tolerance may be discovered as we
gain a greater understanding of the intricacies of interaction
networks shaping collective tolerance within bacterial
communities.
Conclusion
Bacteria typically coexist in complex multi-species com-
munities and the interactions within these communities can
dictate how bacteria respond to antibiotic exposure. This
has important clinical, ecological and environmental con-
sequences, altering levels of tolerance, the selection of
resistance and the trajectory of resistance evolution. Con-
ventionally, conclusions about the antibiotic susceptibility
of a pathogen are drawn from pure culture measurements of
cells in a generally homogenous state. Such information
may be adequate for the treatment of infections caused by a
single strain. However, it may not be informative of the
antibiotic susceptibility of a focal pathogen during poly-
microbial infection or embedded within a commensal
microbial community. We propose that to effectively design
antimicrobial stewardship for pathogens residing in com-
munities we need to view antibiotic resistance as an emer-
gent property that arises as a result of combined effects
of antibiotic exposure and microbial interactions within
communities.
While understanding AMR in a community context is
challenging given the diversity and complexity of microbial
interaction networks, it can be achieved through the careful
combination of complementary approaches: (1) antibiotic
susceptibility testing, where appropriate, should be conducted
upon communities in addition to single-cell cultures because
resistance is determined by the interactions taking place
within that specific community; (2) This should be combined
with analyses exploring the consequences of antibiotic
treatments on community structure and functioning, which
could further change community susceptibility to antibiotics
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during long term or repeated treatments which are common
in chronic, polymicrobial infections; (3) The evolutionary
responses to antibiotic treatment should not only focus on the
focal pathogen but also upon the wider community in which
it resides, as the community is likely to alter the selection
dynamics of resistance or could act as reservoir for antibiotic
genes. While the effect of ecological context upon antibiotic
resistance is important in clinical environments, it should also
be addressed in natural microbial communities that are reg-
ularly exposed to antibiotic residues through contaminated
manure, sewage and wastewater. Moreover, it will also be
necessary to move beyond bacterial interactions to also
consider the role of multi-kingdom interactions in AMR in
the future. Studies increasingly highlight the importance of
microbial ecology in determining tolerance, resistance and
evolutionary responses to antibiotic treatment, further con-
sideration and quantification of interactions within bacterial
community should be paramount.
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